Telehealth company Hims & Hers Health (NYSE:HIMS) reported Q1 CY2025 results topping the market’s revenue expectations, with ...

Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But the company ...

For Q1 2025, Hims & Hers posted adjusted earnings per share of $0.20, missing the analyst consensus of $0.23. However, ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

Hims & Hers Health first-quarter revenue more than doubled as subscribers rose 38%, while its second-quarter sales outlook ...

Hims & Hers Health announced Nader Kabbani will join the telehealth company as its new chief operations officer. Kabbani ...

Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Nader ...

About Hims & Hers Health Inc. Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for ...